1. Klein U, Dalla-Favera R. Germinal Centres: Role in B-Cell Physiology and Malignancy. Nat Rev Immunol 2008; 8(1): 22-33. [
DOI:10.1038/nri2217]
2. Nakaya A, Fujita S, Satake A, et al. Impact of CRAB Symptoms in Survival of Patients with Symptomatic Myeloma in Novel Agent Era. Hematol Rep 2017; 9(1): 6887. [
DOI:10.4081/hr.2017.6887]
3. Nutt SL, Hodgkin PD, Tarlinton DM, et al. The Generation of Antibody-Secreting Plasma Cells. Nat Rev Immunol 2015; 15(3): 160-71. [
DOI:10.1038/nri3795]
4. Zhan F, Huang Y, Colla S, et al. The Molecular Classification of Multiple Myeloma. Blood 2006; 108(6): 2020-28. [
DOI:10.1182/blood-2005-11-013458]
5. Manzanera MG, Izquierdo SJ, Matos OA. Immunophenotyping of Plasma Cells in Multiple Myeloma. Methods Mol Med 2005; 113: 5-24. [
DOI:10.1385/1-59259-916-8:5]
6. Gooding PR, Bybee A, Cooke A, et al. Phenotypic and Molecular Analysis of Six Human Cell Lines Derived from Patients with Plasma Cell Dyscrasia. Br J Haematol 1999; 106(3): 669-81. [
DOI:10.1046/j.1365-2141.1999.01602.x]
7. Bakhtiari M, Kaviani S, Abroon S, Moallemi M, Jalaei Kho H. Amniotic Fluid that Supports the Growth of Plasma Cells. Iran South Med J 2018; 21(4): 304-318.
8. Seegmiller AC, Xu Y, McKenna RW, et al. Immunophenotypic Differentiation between Neoplastic Plasma Cells in Mature B-cell lymphoma vs Plasma Cell Myeloma. Am J Clin Pathol 2007; 127(2): 176-81. [
DOI:10.1309/5EL22BH45PHUPM8P]
9. Flores-Montero J, De Tute R, Paiva B, et al. Immunophenotype of Normal vs. Myeloma Plasma Cells: Toward Antibody Panel Specifications for MRD Detection in Multiple Myeloma. Cytometry B Clin Cytom 2016; 90(1): 61-72. [
DOI:10.1002/cyto.b.21265]
10. Kawano Y, Fujiwara S, Wada N, et al. Multiple Myeloma Cells Expressing Low Levels of CD138 Have an Immature Phenotype and Reduced Sensitivity to Lenalidomide. Int J Oncol 2012; 41(3): 876-84. [
DOI:10.3892/ijo.2012.1545]
11. Togawa A, Inoue N, Miyamoto K, et al. Establishment and Characterization of a Human Myeloma Cell Line (KMM-1). Int J Cancer 1982; 29(5): 495-500. [
DOI:10.1002/ijc.2910290502]
12. Moreaux J, Klein B, Bataille R, et al. A High-Risk Signature for Patients with Multiple Myeloma Established from the Molecular Classification of Human Myeloma Cell Lines. Haematologica 2011; 96(4): 574-82. [
DOI:10.3324/haematol.2010.033456]
13. Vincent Rajkumar S. Multiple Myeloma: 2018 Update on Diagnosis, Risk‐Stratification, and Management. Am J Hematol 2018; 93(8): 1091-110. [
DOI:10.1002/ajh.25117]
14. Drexler HG, Matsuo Y. Malignant Hematopoietic Cell Lines: in Vitro Models for the Study of Multiple Myeloma and Plasma Cell Leukemia. Leuk Res 2000; 24(8): 681-703. [
DOI:10.1016/S0145-2126(99)00195-2]
15. Ohtsuki T, Yawata Y, Wada H, et al. Two Human Myeloma Cell Lines, Amylase-Producing KMS-12-PE and Amylase-Non-Producing KMS-12-BM, Were Established from a Patient, Having the Same Chromosome Marker, t(l1;14)(ql3;q32). Br J Haematol 1989; 73(2): 199-204. [
DOI:10.1111/j.1365-2141.1989.tb00252.x]
16. Klein U, Dalla-Favera R. Germinal Centres: Role in B-Cell Physiology and Malignancy. Nat Rev Immunol 2008; 8(1): 22-33. [
DOI:10.1038/nri2217]
17. Nakaya A, Fujita S, Satake A, et al. Impact of CRAB Symptoms in Survival of Patients with Symptomatic Myeloma in Novel Agent Era. Hematol Rep 2017; 9(1): 6887. [
DOI:10.4081/hr.2017.6887]
18. Nutt SL, Hodgkin PD, Tarlinton DM, et al. The Generation of Antibody-Secreting Plasma Cells. Nat Rev Immunol 2015; 15(3): 160-71. [
DOI:10.1038/nri3795]
19. Zhan F, Huang Y, Colla S, et al. The Molecular Classification of Multiple Myeloma. Blood 2006; 108(6): 2020-28. [
DOI:10.1182/blood-2005-11-013458]
20. Manzanera MG, Izquierdo SJ, Matos OA. Immunophenotyping of Plasma Cells in Multiple Myeloma. Methods Mol Med 2005; 113: 5-24. [
DOI:10.1385/1-59259-916-8:5]
21. Gooding PR, Bybee A, Cooke A, et al. Phenotypic and Molecular Analysis of Six Human Cell Lines Derived from Patients with Plasma Cell Dyscrasia. Br J Haematol 1999; 106(3): 669-81. [
DOI:10.1046/j.1365-2141.1999.01602.x]
22. Bakhtiari M, Kaviani S, Abroon S, Moallemi M, Jalaei Kho H. Amniotic Fluid that Supports the Growth of Plasma Cells. Iran South Med J 2018; 21(4): 304-318.
23. Seegmiller AC, Xu Y, McKenna RW, et al. Immunophenotypic Differentiation between Neoplastic Plasma Cells in Mature B-cell lymphoma vs Plasma Cell Myeloma. Am J Clin Pathol 2007; 127(2): 176-81. [
DOI:10.1309/5EL22BH45PHUPM8P]
24. Flores-Montero J, De Tute R, Paiva B, et al. Immunophenotype of Normal vs. Myeloma Plasma Cells: Toward Antibody Panel Specifications for MRD Detection in Multiple Myeloma. Cytometry B Clin Cytom 2016; 90(1): 61-72. [
DOI:10.1002/cyto.b.21265]
25. Kawano Y, Fujiwara S, Wada N, et al. Multiple Myeloma Cells Expressing Low Levels of CD138 Have an Immature Phenotype and Reduced Sensitivity to Lenalidomide. Int J Oncol 2012; 41(3): 876-84. [
DOI:10.3892/ijo.2012.1545]
26. Togawa A, Inoue N, Miyamoto K, et al. Establishment and Characterization of a Human Myeloma Cell Line (KMM-1). Int J Cancer 1982; 29(5): 495-500. [
DOI:10.1002/ijc.2910290502]
27. Moreaux J, Klein B, Bataille R, et al. A High-Risk Signature for Patients with Multiple Myeloma Established from the Molecular Classification of Human Myeloma Cell Lines. Haematologica 2011; 96(4): 574-82. [
DOI:10.3324/haematol.2010.033456]
28. Vincent Rajkumar S. Multiple Myeloma: 2018 Update on Diagnosis, Risk‐Stratification, and Management. Am J Hematol 2018; 93(8): 1091-110. [
DOI:10.1002/ajh.25117]
29. Drexler HG, Matsuo Y. Malignant Hematopoietic Cell Lines: in Vitro Models for the Study of Multiple Myeloma and Plasma Cell Leukemia. Leuk Res 2000; 24(8): 681-703. [
DOI:10.1016/S0145-2126(99)00195-2]
30. Ohtsuki T, Yawata Y, Wada H, et al. Two Human Myeloma Cell Lines, Amylase-Producing KMS-12-PE and Amylase-Non-Producing KMS-12-BM, Were Established from a Patient, Having the Same Chromosome Marker, t(l1;14)(ql3;q32). Br J Haematol 1989; 73(2): 199-204. [
DOI:10.1111/j.1365-2141.1989.tb00252.x]